Novo Nordisk Goes ‘Full-Speed Ahead’ Towards Once-Weekly Basal Insulin
Readouts to all six ONWARDS trials to come in 2022, Development Head Says
Novo Nordisk’s once-weekly injected basal insulin icodec could be a boon to the many people with type 2 diabetes who are reluctant to start on insulin therapy due to the need for daily injections, the Danish group’s head of development tells Scrip.
You may also be interested in...
Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.
A surprise surge in Roche's R&D spending this year reflects high quality in-house innovation opportunities as well as high prices for external M&A targets, management said.
Roche unveiled a strong Q2 performance driven by new medicines and continued strong growth from its diagnostics division but analysts were most keen for clues on plans for gantenerumab, now in Phase III studies for Alzheimer’s disease.